Join Growin Stock Community!

Cellyan biotechnology co., ltdHKPD.US Overview

US StockConsumer Defensive
(No presentation for HKPD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HKPD AI Insights

HKPD Overall Performance

HKPD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HKPD Recent Performance

-1.52%

Cellyan biotechnology co., ltd

-1.34%

Avg of Sector

-0.31%

S&P500

HKPD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HKPD Key Information

HKPD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HKPD Profile

Hong Kong Pharma Digital Technology Holdings Ltd. engages in providing pharmaceutical cross-border e-commerce supply chain services. It focuses on cross-border pharmaceutical warehousing, cross-border OTC registration and import, and OTC product wholesale services. The company was founded by Lap Sun Wong on August 17, 2023 and is headquartered in Hong Kong.

Price of HKPD

HKPD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HKPD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.36
PB Ratio
1.47
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.36
PB Ratio
1.47
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is HKPD's latest earnings report released?

    The most recent financial report for Cellyan biotechnology co., ltd (HKPD) covers the period of 2025Q2 and was published on 2024/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HKPD's short-term business performance and financial health. For the latest updates on HKPD's earnings releases, visit this page regularly.

  • How much debt does HKPD have?

    As of the end of the reporting period, Cellyan biotechnology co., ltd (HKPD) had total debt of 2.37M, with a debt ratio of 0.23. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HKPD have?

    At the end of the period, Cellyan biotechnology co., ltd (HKPD) held Total Cash and Cash Equivalents of 749.12K, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.